NASDAQ
Cardiff Oncology, Inc. (CRDF)
♥ 338 Thanks from members
Cardiff Oncology, Inc. (CRDF) displays strong Phase II clinical data for its lead asset onvansertib in mCRC, contrasted by financial headwinds, a licensing dispute with Nerviano (NMS), and downgraded analyst ratings following potential patent and inventorship challenges.